Anacor price target raised to $80 from $70 at Jefferies Jefferies analyst David Steinberg raised his price target for Anacor Pharmaceuticals to $80 from $70 saying Kerydin continues to exceed expectations. Sandoz has now fully completed its planned sales force expansion for the toenail fungus treatment, Steinberg tells investors in a research note, citing his industry contacts. Further, pivotal AN2728 Phase 3 data is expected in the coming weeks, the analyst points out. He ascribes 80% odds to a positive readout for the atopic dermatitis candidate, which he feels could push the shares past $100. Steinberg keeps a Buy rating on Anacor.
Anacor price target raised to $85 from $72 at Wedbush Wedbush believes that sales of Anacor's Kerydin drug have been impressive and could cause the company's Q2 results to beat expectations. The firm significantly raised its 2015-2017 Kerydin sales estimates and keeps an Outperform rating on Anacor.